Genomics solutions provider Annoroad has secured a $100 million Series C, while AI-based chatbot developer Zhuiyi Technology has raised $20.6 million in a round led by Sinovation Ventures.
Annoroad raises $100m Series C
Beijing-based genomics solutions provider Annoroad has raised a $100 million Series C led by Shenzhen-based investment firm Shenzhen GTJA Investment Group and Ping An Insurance-backed Ping An Ventures.
Annoroad works in the areas of handling molecular diagnostic reagents, medical analysis, medical research, gene Big Data and cloud platform.
Working on both clinical testing and life science research, Annoroad has developed a series of next-generation sequencing (NGS) diagnostic applications in the field of human reproduction, cancer, and rare diseases.
Just three months ago, Annoroad announced the release of SolarGenomics, a cloud-based platform that seeks to provide a one-stop shop for bioinformatics pipelines and data storage infrastructure.
In 2015, it entered into a joint agreement with Illumina, a leader in genomics industry in China, to develop advanced clinical applications for reproductive health using NGS technology.
Sinovation Ventures leads $20.6m round in Zhuiyi
The round was joined by GGV Capital, Banyan Capital and Morningside Ventures.
Its chatbot is used largely for customer services in sectors including finance, Internet, tourism, retail, real estate and education. Customers include Didi Chuxing, bike sharing firm ofo, smartphone developer Xiaomi Inc. and China Merchants Bank.
The firm had raised an undisclosed seven-digit Series A last year from Banyan and Morningside. Eight months before that, it raised a seven-digit round from Morningside.